Skip to content
Obesity
-
-
-
-
-
-
-
-
-
Amgen’s breakthrough obesity drug AMG 133 sparks investor frenzy
During Amgen’s recent fourth-quarter earnings call conference on Tuesday, February 6, Wall Street analysts were enthusiastic about the prospects of AMG 133, an experimental GLP-1 drug intended for the treatment of obesity.
-
